DHR Jan 2024 240.000 put
| Previous close | 18.00 |
| Open | 16.20 |
| Bid | 16.40 |
| Ask | 17.10 |
| Strike | 240.00 |
| Expiry date | 2024-01-19 |
| Day's range | 16.10 - 17.13 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.14k |
ZacksDanaher (DHR) Gains As Market Dips: What You Should Know
Danaher (DHR) closed at $237.52 in the latest trading session, marking a +1.22% move from the prior day.
ZacksDanaher (DHR) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Danaher (DHR) closed at $232.69, marking a +1.34% move from the previous day.
ZacksDanaher (DHR) Gains But Lags Market: What You Should Know
Danaher (DHR) closed the most recent trading day at $232.21, moving +0.76% from the previous trading session.
PR Newswire AsiaBeckman Coulter Unveils Next Generation Immunoassay Analyzer Enabling Elite Laboratory Performance with No Daily Maintenance
Beckman Coulter, a clinical diagnostics leader, today unveiled the DxI 9000 Access Immunoassay Analyzer, the most productive immunoassay analyzer per footprint. The DxI 9000 Analyzer can run up to 215 tests per hour per square meter (tests/hr/m2).
ZacksHoneywell (HON) Beats on Q1 Earnings, Raises FY23 Guidance
Honeywell's (HON) Q1 results benefit from strong performance of the Aerospace segment due to higher commercial aviation aftermarket sales. The company's improved guidance for 2023 holds promise.
Motley FoolThese 2 Large-Cap Laggards Are Leading Markets Lower Tuesday
Stocks got off to a tough start on Tuesday, as market participants looked closely at the latest slate of earnings results. United Parcel Service (NYSE: UPS) is a stalwart of the shipping industry, and its numbers say a lot about whether the e-commerce side of the consumer retail economy is firing on all cylinders. Meanwhile, Danaher (NYSE: DHR) gave its reading on the healthcare sector.
ZacksDanaher (DHR) Q1 Earnings Beat, Revenues Decline 7% Y/Y
Danaher's (DHR) Q1 earnings and revenues beat estimates. However, a decline in the sale of COVID-related products weigh on the top line.
ZacksCompared to Estimates, Danaher (DHR) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Danaher (DHR) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ZacksDanaher (DHR) Surpasses Q1 Earnings and Revenue Estimates
Danaher (DHR) delivered earnings and revenue surprises of 4.42% and 1.97%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksThe Zacks Analyst Blog Highlights Walmart, Chevron, Danaher, Intel and Lowe's
Walmart, Chevron, Danaher, Intel and Lowe's are included in this Analyst Blog.
ZacksTop Analyst Reports for Walmart, Chevron & Danaher
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Chevron Corporation (CVX) and Danaher Corporation (DHR).
ZacksDanaher (DHR) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Danaher (DHR) closed at $254.76, marking a -0.54% move from the previous day.
ZacksAnalysts Estimate Danaher (DHR) to Report a Decline in Earnings: What to Look Out for
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Motley FoolWhy Catalent Stock Slumped on Monday
Contract drug manufacturer Catalent (NYSE: CTLT) was surely tempted to reach for the aspirin bottle on Monday. Bloomberg reported that morning that the conglomerate Danaher (NYSE: DHR) has dropped its pursuit of Catalent. Citing "people familiar with the matter," the Bloomberg report said Danaher is no longer considering making a buyout offer despite its earlier expression of interest.
- Zacks
Can Danaher (DHR) Retain Beat Streak This Earnings Season?
Steady demand across end markets within the Life Sciences segment is likely to have aided Danaher's (DHR) Q1 performance. However, cost and supply-chain woes might have hurt the same.
ZacksTime to Buy Stock in These Conglomerates?
With their extensive reach, here are three conglomerates' investors may want to consider as they are top-rated Zack stocks at the moment.
ZacksDanaher (DHR) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Danaher (DHR) closed at $250.09, marking a -0.77% move from the previous day.
- Zacks
Here's Why You Should Hold on to Danaher (DHR) Stock Now
The DBS initiatives, cost management actions and steady demand across major end markets augur well for Danaher's (DHR) growth. Handsome rewards to shareholders add to the stock's appeal.
- Zacks
HTHIY vs. DHR: Which Stock Should Value Investors Buy Now?
HTHIY vs. DHR: Which Stock Is the Better Value Option?
ZacksDanaher (DHR) Stock Moves -1.67%: What You Should Know
In the latest trading session, Danaher (DHR) closed at $243.63, marking a -1.67% move from the previous day.
ZacksThe Zacks Analyst Blog Highlights NVIDIA, Visa, Toyota Motor, Costco Wholesale and Danaher
NVIDIA, Visa, Toyota Motor, Costco Wholesale and Danaher are included in this Analyst Blog.
ZacksTop Stock Reports for NVIDIA, Visa & Toyota Motor
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Visa Inc. (V), and Toyota Motor Corporation (TM).
ZacksHTHIY or DHR: Which Is the Better Value Stock Right Now?
HTHIY vs. DHR: Which Stock Is the Better Value Option?
Motley FoolGot $300? 3 Growth Stocks to Buy That Could Double Your Money
For investors looking to double their money, look for healthcare stocks that are consistently increasing revenue and earnings per share (EPS). Cigna Group (NYSE: CI), Danaher (NYSE: DHR), and IQVIA Holdings (NYSE: IQV) all have managed to generate double-digit (or higher) increases in either quarterly revenue and earnings per share, or both, over the past five years. Let's find out a bit more about these three growth stocks.
ZacksCatalent (CTLT) Surges on Rumors of Acquisition by Danaher
Catalent (CTLT) shares gain significantly, following a Bloomberg report about a potential acquisition of the CDMO company by Danaher, a life sciences company.
